Our results are in line with previous studies in prostate cancer, where it was shown that when overexpressing the UGDH enzyme during androgen treatment (similarly eliminated by glucuronidation), the synthesis of HA was not stimulated, although HAS3 expression was increased [51]. The gene discussed is HAS3; the disease is prostate carcinoma.